RBC Capital Mkts has recently raised IGM Biosciences Inc (IGMS) stock to Outperform rating, as announced on February 9, 2024, according to Finviz. Earlier, on December 15, 2023, BofA Securities had reduced the stock from a Buy to Neutral, setting a price target of $8. H.C. Wainwright also reduced Neutral rating with a price target of $7. Additionally, Jefferies resumed Buy rating on November 9, 2022, with a target price of $55. JP Morgan analysts, in their report published on October 17, 2022, also initiated Neutral rating for IGM Biosciences Inc’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Sponsored
IGM Biosciences Inc (IGMS) Stock Trading Recap
On Monday, IGM Biosciences Inc (IGMS) stock saw a decline, ending the day at $16.54 which represents a decrease of $-0.46 or -2.71% from the prior close of $17. The stock opened at $16.7 and touched a low of $15.5 during the day, reaching a high of $18.38. The volume of shares traded was 0.76 million exceeding the average volume of 0.33 million.
IGMS Stock Performance and Moving Averages
In recent trading, IGM Biosciences Inc (IGMS) stock price has shown some volatility, fluctuating 3.44% over the last five trades and 60.43% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by 75.03%, and it has gained 143.59% in the previous three months. Currently, IGMS is trading at 21.31%, 44.10%, and 62.97% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, IGMS, a Healthcare sector stock, is trading -26.49% below its 52-week high but remains 334.12% above its 52-week low. The Average True Range (ATR) (14 days) of 1.87 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
IGM Biosciences Inc’s Profitability and Valuation Ratios
IGM Biosciences Inc’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of -8137.82% and a profit margin of -7571.35%, with a gross margin of 75.03%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, IGM Biosciences Inc’s market capitalization stands at $981.15 million. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. Additionally, the Price-to-Sales Ratio is 337.17, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 8.01, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 64.77% of IGM Biosciences Inc (IGMS)’s shares, while financial institutions hold 37.40%.
Notable insider trades include Hambleton Julie, Director at IGM Biosciences Inc (IGMS), who sold 15132 shares on Jul 25 ’24, at $14 each, totaling $0.21 million. On Dec 13 ’23, Schwarzer Fred, CEO and President, sold 17576 shares for $5.78 each, amounting to $0.10 million.
